Market Overview:
The Acute Pancreatitis Market Size was valued at USD 5.5 billion in 2023 and is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2030). The major market driver fueling the expansion is the increased prevalence of gastrointestinal issues.
Acute Pancreatitis Market Trends
Increase in the occurrence of acute pancreatitis to propel market growth
According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 275,000 Americans are hospitalized each year for acute pancreatitis (NIDDK). When the pancreas swells and becomes irritated, pancreatitis (swelling) results. It is not a widespread disease. The most common reasons are gallstones or excessive alcohol consumption. The disease can develop gradually over time or come on suddenly, causing serious injury. Treatment for pancreatitis may include intravenous (IV) fluids, painkillers, and other medications. Rising occurrence of acute pancreatitis globally will be a key factor in increasing the market growth rate. Gallstones and excessive alcohol consumption, especially in young people, are the main causes of acute pancreatitis. Gallstones are the most common cause of AP, accounting for 28-38% of cases, and alcohol consumption is the second most common cause, accounting for 19-41% of cases, according to an article published in the World Journal of Clinical Cases. - Assessment and management of acute pancreatitis in 2019. The likelihood of developing acute pancreatitis increases as the number of people with gallstones increases. Thus, this factor is driving the CAGR of the market.
Additionally, there is growing global interest in understanding the impact of chronic comorbidities on people with acute pancreatitis. Recent research published in BioMed Hub in November 2021 revealed a correlation between gastrointestinal symptoms in the early stages of acute pancreatitis and pre-existing conditions such as metabolic syndrome, obesity and diabetes mellitus. Another PLOS One article from June 2021 points out that obesity is an important public health problem in France, as it increases the likelihood of developing chronic diseases such as diabetes, hypertension and other conditions with psychological and serious social. The increasing prevalence of obesity and its association with excessive eating habits also increases the risk of pancreatitis, contributing to the growth of this market segment. As a result, the acute pancreatitis market is expected to grow steadily throughout the forecast period, driven by factors such as rising prevalence of obesity and growing use of intravenous therapy.
However, the sector will increase as the elderly population grows and government awareness efforts are implemented. Furthermore, changing consumer lifestyles and increasing government-welcoming policies will propel market growth. An growth in the number of R&D activities is another factor driving the market's expansion. As a consequence, this aspect is likely to increase acute pancreatitis market revenue globally.
Acute Pancreatitis Market Segment Insights:
Acute Pancreatitis Cause Insights
Gallstones, alcohol, and other factors are among the causes of Acute Pancreatitis Market segmentation. According to Acute Pancreatitis Market statistics, the gallstones category held the most share in 2023. Acute pancreatitis is becoming more common over the world, as are gallstones. Gallstones cause around 40% of instances of acute pancreatitis. Gallstones afflict around 20 million people in the United States. Approximately 300,000 cholecystectomies are done on these individuals each year.
Acute Pancreatitis Treatment Insights
The therapy segmentation of the Acute Pancreatitis Market covers intravenous fluid, nutritional assistance, analgesics, endoscopic retrograde cholangiopancreatography (ERCP), and others. The intravenous fluid segment dominated market growth in 2023 and is expected to be the fastest-growing segment during the forecast period, 2023-2030, owing to factors such as the increased prevalence of acute pancreatitis, gallstones, and obesity in the population, as well as the risk factors associated with them. Acute pancreatitis is connected with dehydration and extreme fluid loss, which can be lethal and end in the patient's death. Intravenous fluid supply keeps the body hydrated, ensuring adequate blood flow to the other organs.
Acute Pancreatitis Diagnosis Insights
Based on diagnosis, the Acute Pancreatitis Market data covers imaging tests and laboratory testing. The laboratory testing category led the acute pancreatitis market revenue in 2023 and is expected to increase at the fastest rate during the forecast period, 2023-2030. Amylase and lipase are important pancreatic enzymes that may be detected through laboratory testing. The following may cause blood to gush. Other blood tests can be performed to detect gallbladder obstruction or injury.
Acute Pancreatitis End-User Insights
End-users in the worldwide acute pancreatitis sector include hospitals, clinics, and others. Hospitals led the market in 2023 and are expected to be the fastest-growing sector throughout the forecast period, 2023-2030. The fact that hospitals are usually well-stocked and offer all services under one roof motivates patients with acute pancreatitis to seek treatment there. Another factor driving rising hospital visits is the increasing penetration of connected devices and equipment.
Acute Pancreatitis Regional Insights
According to the research, the market is classified into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. The acute pancreatitis market in North America is expected to reach USD 2.5 billion in 2023, with a share of around 45.80%, and to grow at a rapid CAGR throughout the research period. Acute pancreatitis, obesity, and gallstones are all on the rise. These factors, together with a well-established healthcare infrastructure and high healthcare spending, are driving market expansion.
Significant countries included in the market study are the United States, Canada, Germany, France, the United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
The Asia Pacific acute pancreatitis market is the world's second biggest. The risk of pancreatic inflammation has increased as a result of growing obesity rates caused by changing lifestyles, which is projected to fuel market growth. Acute pancreatitis pharmaceutical and device-based therapies are expected to be in high demand, driving market development as R&D efforts in the area expand. Furthermore, the acute pancreatitis market in China was the largest, while the acute pancreatitis market in India was the fastest growing.
Between 2023 and 2030, Europe's acute pancreatitis market is predicted to develop at the quickest CAGR. This is due to growing demand for certain drugs, and rising healthcare expenditures will accelerate market expansion in this area even more. The presence of significant competitors, as well as growing usage of newer technologies, will hasten market development in this business. Furthermore, the acute pancreatitis market in the United Kingdom was the largest, while the acute pancreatitis market in Germany was the fastest expanding.
Acute Pancreatitis Market Barriers
The acute pancreatitis market faces several barriers. Firstly, the complex and multifactorial nature of the disease makes it challenging to develop targeted therapies. Limited understanding of the underlying mechanisms and pathogenesis further hinders the development of effective treatments. Additionally, the lack of specific diagnostic biomarkers poses challenges in accurately identifying and diagnosing the disease. The high cost of treatment, including hospitalization and intensive care, creates financial barriers for patients. Moreover, the high rate of complications and mortality associated with severe cases of acute pancreatitis presents significant challenges in improving patient outcomes. Regulatory hurdles and the lengthy drug approval process also contribute to the barriers in bringing new therapies to the market. Overall, these barriers highlight the need for continued research, innovative approaches, and collaborative efforts to address the challenges in the acute pancreatitis market.
Acute Pancreatitis Market Challenges
The acute pancreatitis market faces several challenges. Firstly, the lack of specific diagnostic tests often leads to delays in accurate diagnosis and appropriate treatment initiation. The disease's heterogeneous nature and varying severity levels pose challenges in determining the optimal management approach. Additionally, the high rate of complications, such as pancreatic necrosis and infection, increases the complexity of treatment and contributes to poor patient outcomes. The limited effectiveness of current therapies for severe cases of acute pancreatitis further adds to the challenges in improving patient outcomes. Moreover, the significant healthcare costs associated with hospitalization, intensive care, and long-term management pose financial burdens for both patients and healthcare systems. Addressing these challenges requires advancements in diagnostic techniques, development of targeted therapies, and improved understanding of the disease mechanisms to optimize treatment strategies and enhance patient care.
Acute Pancreatitis Key Market Players & Competitive Insights
Major market players are extensively spending in R&D to increase their product lines, which will help the acute pancreatitis market grow even more. Participants in the market are also adopting a range of strategic initiatives to grow their worldwide presence, such as new product releases, contractual agreements, mergers and acquisitions, increased investments, and cooperation with other companies. Acute pancreatitis competitors must offer cost-effective items in order to flourish and thrive in a more competitive and rising market climate.
Manufacturing locally to reduce operating costs is a key business strategy utilised by manufacturers in the global acute pancreatitis industry to better service clients and grow the market sector. In recent years, the acute pancreatitis sector has offered some of the most significant medical advantages. The acute pancreatitis market is led by SCM Lifescience, General Electric Company, CalciMedica, B. Braun Melsungen AG, Samsung Bioepis, Medtronic, Boston Scientific Corporation, Baxter International Inc., Fresenius Kabi USA, and GNT Pharma Co.
CalciMedica, a biopharmaceutical company in the clinical stage for the treatment of inflammatory illnesses like COVID-19 pneumonia and acute pancreatitis, are developing inhibitors of CRAC channels. Calcium, a crucial messenger chemical, must be transported into different types of cells through CRAC channels. CalciMedica has created a portfolio of wholly-owned CRAC channel inhibitors and unique assays to maximize chemical leads. In December 2023, auxora is the subject of Phase II clinical dose-ranging study by CalciMedica, Inc. in patients with acute pancreatitis and systemic inflammatory response syndrome.
The corporate headquarters of the American healthcare giant Baxter International Inc. is located in Deerfield, Illinois. The company's main areas of concentration include chronic and urgent medical issues, including kidney illness. Sales for the company's two segments, BioScience and Medical Products, totaled $10.6 billion in 2017. Recombinant and blood plasma proteins, plasma-based therapies, products for regenerative medicine, and vaccines are all produced by Baxter's BioScience division to treat hemophilia and other bleeding disorders, immunological deficiencies, and other chronic and acute blood-related illnesses.
Key Companies in the acute pancreatitis market includes
- CalciMedica
- SCM Lifescience
- Samsung Bioepis
- GNT Pharma Co.
- Baxter International Inc.
- Braun Melsungen AG
- General Electric Company
- Medtronic
- Boston Scientific Corporation
- Fresenius Kabi USA
Acute Pancreatitis Industry Developments
March 2023: Nafamostat and citrate anticoagulation (RCA), two distinct dialysis circuit anticoagulants, were compared in pediatric patients receiving continuous renal replacement treatment by AcelRx Pharmaceuticals, Inc. (CRRT). A serine protease inhibitor called nafamostat is used to treat acute pancreatitis.
January 2021: Olinvyk (oliceridine), an opioid-based medication, was introduced by Trevena, Inc. for treating acute pain. FDA authorized Olinvyk (oliceridine) in August 2020. Oliceridine, a Schedule II-restricted opioid-like drug with a high potential for abuse, is a component of OLINVYK.
Acute Pancreatitis Market Segmentation
Acute Pancreatitis Cause Outlook (USD Billion, 2018-2030)
- Gallstones
- Alcohol
- Others
Acute Pancreatitis Treatment Outlook (USD Billion, 2018-2030)
- Intravenous fluid
- Nutritional support
- Analgesics
- Endoscopic Retrograde Cholangiopancreatography (ERCP)
- Others
Acute Pancreatitis Diagnosis Outlook (USD Billion, 2018-2030)
- Imaging Tests
- Laboratory Tests
Acute Pancreatitis End-user Outlook (USD Billion, 2018-2030)
- Hospitals
- Clinics
- Others
Acute Pancreatitis Regional Outlook (USD Billion, 2018-2030)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America